Cancer Genetics (CGIX) Tops Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts CGIX Hot Sheet
Join SI Premium – FREE
Cancer Genetics (NASDAQ: CGIX) reported Q1 EPS of ($0.44), $0.10 better than the analyst estimate of ($0.54). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $3.91 million.
For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Arm Holdings stock sinks amid broad chip sector selloff
- SanDisk stock tumbles as Kioxia warns on NAND price surge
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
